Views & Analysis Infographic: Solving the challenges of immuno-oncology trial... The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the former one-size-fits-all approach to a more personalised methodology.
News Kymab signs immuno-oncology deal for bi-specific antibodies UK and Chinese antibody companies collaborate in immuno-oncology
News Some good news for BMS with Opdivo + natural killer cell com... But BMS dumps combination with Yervoy.
Views & Analysis Immuno-oncology: how to keep ahead in a fast-moving field In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.
Partner Content Partner Content Ensuring a more informed and effective oncology drug develop... The rush to discover the next big frontier in cancer medicine is more evident than it ever has been since the introduction of targeted therapies.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.